4//SEC Filing
Martin Samuel Bates 4
Accession 0001415889-24-015147
CIK 0000744218other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:05 PM ET
Size
9.3 KB
Accession
0001415889-24-015147
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2024-05-30$10.38/sh+25,000$259,500→ 60,128 total - Sale
Common Stock
2024-05-30$34.05/sh−35,000$1,191,775→ 25,128 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-05-30−25,000→ 80,600 totalExercise: $10.38Exp: 2030-06-18→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F2]25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Documents
Issuer
Celldex Therapeutics, Inc.
CIK 0000744218
Entity typeother
Related Parties
1- filerCIK 0001709024
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 4:05 PM ET
- Size
- 9.3 KB